Algeta ASA - Notice of Annual General Meeting 2007
Please find notice of Annual General Meeting in Algeta ASA enclosed.
The Annual General Meeting will be held on May 10 at 18:30 hours in Oslo Konserthus, Lille Sal, Munkedamsveien 14 Oslo. Please use main entrance from Johan Svendsens plass / Ruseløkkveien Oslo, Norway.
Printed edition of the notice is this week being sent by mail to Algeta's shareholders.
For further information, please contact
Dr Thomas Ramdahl, CEO +47 23 00 79 90 / +47 913 91 458 (mob) firstname.lastname@example.org
Geir Christian Melen, CFO +47 23 00 79 84 / +47 913 02 965 (mob) email@example.com
Algeta ASA is a Norwegian cancer therapeutics company built on world-leading, proprietary technology.
Algeta is developing new targeted cancer therapeutics that harness the unique characteristics of alpha particle emitters and are potent, well-tolerated and convenient to use.
Algeta's lead product candidate, Alpharadin, is expected to enter Phase III clinical trials in hormone refractory prostate cancer based on positive Phase II results. Alpharadin is a novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal metastases from multiple cancer types, as well as primary bone cancers.
Algeta is also developing other technologies for delivering alpha emitters. These include microparticles, liposomes, and methods to enhance the potency of therapeutic antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227.
The Company is headquartered in Oslo, Norway, and was founded in 1997. Algeta listed on the Oslo Stock Exchange in March 2007 (Ticker: ALGETA).
Alpharadin and Algeta are trademarks of Algeta ASA.